Comparative bioavailaibilty of two valproic acid delayed-release tablets in healthy volunteers with tighter acceptance criteria to anticipate breakthrough seizures

Budi Prasaja, Yahdiana Harahap, Windy Lusthom, Hardiyanti, Theresia Sinandang, Lia Y. Yusvita, Desy Puspita, Uci Chilmi, Thomas Anggun

Research output: Contribution to journalArticle

Abstract

The present study was performed to investigate if the generic of valproic acid delayed release is interchangeable on the basis bioequivalence to the reference product. Due to previous report of breakthrough seizures following a change from a brand name product to a generic product, this bioequivalence study was conducted using tightened acceptance criteria for assuring the therapeutic equivalence. Twenty eight healthy volunteers participated in an open-label, randomized and two-way crossover study under fasting conditions. Plasma samples were collected up 72 hours following drug administration and were determined by liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters used for bioequivalence assessment were AUC0-t, AUC0-∞, and Cmax. The 90% CI bioequivalence limits was tightened from the traditional 80.00% -125.00% to 90.00%-111.11%. All volunteers completed the study. The 90% confidence intervals obtained by analysis of variance for AUC0-t, AUC0-∞, and Cmax were 98.38%-104.61%, 98.93%-105.31%, and 92.62%-102.93%, respectively. Both formulations were tolerated and no serious adverse events were reported. These results were all within the range of 90.00-111.11%. The low intra-subject variability observed in this study indicates that tightened acceptance criteria are still applicable for valproic acid BE study.

Original languageEnglish
Pages (from-to)12-18
Number of pages7
JournalPharmaceutical Sciences Asia
Volume46
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • Bioavailability
  • Delayed-release tablet
  • Pharmacokinetic
  • Valproic acid

Fingerprint Dive into the research topics of 'Comparative bioavailaibilty of two valproic acid delayed-release tablets in healthy volunteers with tighter acceptance criteria to anticipate breakthrough seizures'. Together they form a unique fingerprint.

Cite this